13F Holdings
中文EN

QURE uniQure N.V.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1590560 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY28.0%
TTM net income YoY1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR-43.5%
Net income 3-yr CAGR—

Margins

Gross margin93.9%
Operating margin-1,001.7%
Net margin-1,154.8%
FCF margin-956.8%
EBITDA margin-921.0%

Returns

ROE-89.0%
ROA-25.5%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets68.7%
Debt / equity0.17x
Current ratio11.52x
Interest coverage-3.51x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue3.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$16.10M$27.12M$15.84M$106.48M$524.00M
Cost of revenue$1.69M$1.27M$65,000$1.25M$24.98M
Gross profit$14.41M$25.85M$15.78M$105.23M$499.03M
R&D expense$140.67M$143.78M$214.86M$197.59M$143.55M
SG&A expense$65.46M$52.66M$74.59M$55.06M$56.29M
Operating income-$185.35M-$184.29M-$282.87M-$143.16M$310.62M
Interest expense$61.99M$63.74M$41.56M$11.70M$7.47M
Pretax income-$193.34M-$237.13M-$306.56M-$128.26M$332.81M
Income tax$5.63M$2.43M$1.92M-$1.47M$3.22M
Net income-$198.97M-$239.56M-$308.48M-$126.79M$329.59M
EBITDA-$170.59M-$171.65M-$270.97M-$134.96M$316.72M
EPS (basic)-3.46-4.92-6.47-2.717.17
EPS (diluted)-3.46-4.92-6.47-2.717.04
Weighted avg. shares (diluted)57.50M48.65M47.67M46.74M46.84M
Balance sheet
Cash & equivalents$80.24M$160.33M$241.36M$231.17M$559.35M
Receivables$5.86M————
Inventory——$12.02M$6.92M—
Current assets$655.99M$390.29M$651.85M$476.77M$628.24M
PP&E, net$13.80M$20.42M$46.55M$50.53M$43.51M
Goodwill$25.36M$22.41M$26.38M$25.58M$27.63M
Intangibles$72.79M$71.04M$60.48M$58.78M$62.69M
Total assets$824.91M$556.54M$831.69M$704.96M$809.18M
Current liabilities$62.92M$40.05M$73.67M$75.92M$36.76M
Long-term debt$49.70M$51.32M$101.75M$102.79M$100.96M
Total debt$49.70M$51.32M$101.75M$102.79M$100.96M
Total liabilities$626.01M$563.29M$624.02M$228.96M$213.40M
Shareholders' equity$198.90M-$6.75M$207.67M$476.01M$595.78M
Net debt-$30.54M-$109.00M-$139.61M-$128.38M-$458.39M
Shares outstanding62.34M48.99M47.83M46.97M46.30M
Cash flow statement
Operating cash flow-$177.96M-$182.73M-$145.93M-$145.06M$287.96M
Capital expenditure$439,000$3.37M$7.15M$17.69M$17.44M
Free cash flow-$178.40M-$186.10M-$153.08M-$162.75M$270.52M
Investing cash flow-$321.62M$162.97M-$205.69M-$182.73M-$67.39M
Financing cash flow$415.40M-$59.49M$362.72M$1.45M$94.86M
Depreciation & amortization$14.76M$12.64M$11.90M$8.20M$6.10M
Stock-based compensation$17.68M$22.26M$35.09M$34.20M$25.64M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.